Pricing Log in Create free account

Bolt Biotherapeutics, Inc. (BOLT) vs XTL Biopharmaceuticals Ltd. (XTLB)

Bolt Biotherapeutics, Inc. and XTL Biopharmaceuticals Ltd. are both Biotechnology companies. Bolt Biotherapeutics, Inc. and XTL Biopharmaceuticals Ltd. are of similar size ($8.2M and $8.1M). Bolt Biotherapeutics, Inc. grew revenue faster over the last twelve months: 12.8% against −12.7%. XTL Biopharmaceuticals Ltd. has the higher net margin (0.00% vs −611.5%) and the higher return on invested capital (0.00% vs −143.8%). Across the 16 metrics below, XTL Biopharmaceuticals Ltd. leads on 12 and Bolt Biotherapeutics, Inc. on 4.

Valuation

Metric BOLT XTLB Biotechnology median
P/E n/m n/m 8.50
P/S 1.46 1.36 9.71
P/B 0.54 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 1.62 1.27 9.21
Earnings yield (404.93%) (14.29%) (33.15%)
Free cash flow yield (448.90%) (139.25%) (25.50%)

Profitability

Metric BOLT XTLB Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (654.53%) 0.00% 0.00%
Net margin (611.47%) 0.00% 0.00%
Free cash flow margin (655.72%) 0.00% 0.00%
Return on equity (111.65%) 0.00% (56.36%)
Return on assets (49.62%) 0.00% (48.04%)
Return on invested capital (143.75%) 0.00% 0.00%

Growth

Metric BOLT XTLB Biotechnology median
Revenue growth (TTM) 12.79% (12.71%) 6.02%
EPS growth (last fiscal year) 45.91% (159.17%) 30.26%
Revenue growth, 5-year CAGR 101.61% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BOLT XTLB Biotechnology median
Debt to equity 1.47 (1.83) 0.00
Current ratio 2.61 0.70 4.72
Net debt to EBITDA 0.21 (0.11) 0.96

Dividend

Metric BOLT XTLB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BOLT XTLB Biotechnology median
Market cap 8.17m 8.10m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack